Skip to content
Citation only via Europe PMC

Obesity pharmacotherapies and cognition.

Börchers S, Mazzini G, Zetterberg H, Clemmensen C.

Science (New York, N.Y.) · 2026

Abstract

Pharmacotherapies for obesity and type 2 diabetes are increasingly being evaluated for their effects on cognition and brain health. Evidence from preclinical models, observational cohorts, and clinical trials has intensified interest, but findings remain mixed. A central challenge is to determine whether potential cognitive effects arise from direct actions on neural circuits, indirect consequences of improved cardiometabolic health, or both. This Review examines the evidence across cardiometabolic disease, aging, and Alzheimer's disease, focusing on glucagon-like peptide-1 (GLP-1)-based therapies and combination approaches that engage glucose-dependent insulinotropic polypeptide, glucagon, and amylin pathways. We assess how receptor pharmacology, brain exposure, metabolic context, and disease stage shape cognitive outcomes and discuss how mechanistic clarity could guide therapies aimed at preserving or improving cognition.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
Europe PMC
DOI
10.1126/science.aek9987
Canonical
link ↗
Fetched
2026-11-10 MST

Cite this

APA
S, B., G, M., H, Z., &amp; C., C. (2026). Obesity pharmacotherapies and cognition. <em>Science (New York, N.Y.)</em>. https://doi.org/10.1126/science.aek9987
Vancouver
S B, G M, H Z, C. C. Obesity pharmacotherapies and cognition. Science (New York, N.Y.). 2026. doi:10.1126/science.aek9987.
BibTeX
@article{brchers2026Obesit, title = {Obesity pharmacotherapies and cognition.}, author = {Börchers S and Mazzini G and Zetterberg H and Clemmensen C.}, journal = {Science (New York, N.Y.)}, year = {2026}, doi = {10.1126/science.aek9987}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings